Last reviewed · How we verify
PROINSULIN HUMAN
At a glance
| Generic name | PROINSULIN HUMAN |
|---|---|
| Phase | Phase 1 |
Approved indications
Common side effects
- Musculoskeletal
- Infections
- Nervous system
- General Disorders
- Gastrointestinal Disorders
- Injury
- Respiratory
- Skin
- Eye Disorders
- Psychiatric
- Investigations
- Renal
Key clinical trials
- Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D) (PHASE4)
- Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus
- Gestational Diabetes and Pharmacotherapy (GAP) (PHASE4)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (PHASE2)
- Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |